Theravectys raises $20m to progress vaccines pipeline

French vaccines company Theravectys has completed a €14.7m ($20m) financing round, with which it plans to begin a Phase I/II cancer vaccine trial and pursue clinical development of its therapeutic anti-HIV vaccine.